Skip to main content
永顺生物 logo

永顺生物 — Investor Relations & Filings

Ticker · 920729 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 388 across all filing types
Latest filing 2024-12-12 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920729

About 永顺生物

https://www.winsun-gd.com/

Guangdong Winsun Bio-Pharmaceutical Co., Ltd. is a specialized enterprise focused on the research, development, production, and distribution of veterinary biological products. The company primarily develops vaccines for livestock and poultry, with a significant emphasis on swine and avian health. Its product portfolio includes live and inactivated vaccines targeting major diseases such as classical swine fever, porcine reproductive and respiratory syndrome (PRRS), and avian influenza. Winsun Bio-Pharmaceutical leverages advanced biotechnology to provide comprehensive animal disease prevention and control solutions. The company maintains a strong focus on technological innovation and quality management, operating multiple GMP-certified production lines to ensure the efficacy and safety of its biological preparations. Its research initiatives often involve collaborations with academic institutions to advance veterinary medicine and support the animal husbandry sector.

Recent filings

Filing Released Lang Actions
第五届董事会第七次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of the resolutions passed at the company's fifth board of directors' seventh meeting. It details the meeting date, attendance, agenda items, and voting results, specifically regarding a stock incentive plan. There is no financial data, earnings information, or report publication mentioned. The content focuses on board decisions and approvals, which aligns with announcements about board or management information. The document is short (1148 characters) and does not contain or reference a full report but rather a board meeting resolution announcement. Therefore, the appropriate classification is Board/Management Information (MANG).
2024-12-12 Chinese
广东君信经纶君厚律师事务所关于广东永顺生物制药股份有限公司2024年股权激励计划授予事项的法律意见书
Regulatory Filings
2024-12-12 Chinese
上海荣正企业咨询服务(集团)股份有限公司关于广东永顺生物制药股份有限公司 2024年股权激励计划授予事项之独立财务顾问报告
Regulatory Filings
2024-12-12 Chinese
2024年股权激励计划授予权益的激励对象名单（授予日）
Remuneration Information Classification · 95% confidence The document is a public announcement from Guangdong Yongshun Biopharmaceutical Co., Ltd. regarding the list of incentive recipients under the 2024 equity incentive plan. It details the allocation of restricted stock to senior management and core employees, including specific numbers and percentages. The document is signed by the board and dated December 13, 2024. This type of announcement relates to executive compensation and equity incentives, which falls under Remuneration Information filings. It is not a full annual report, audit report, or other financial report, but specifically details compensation-related equity grants to management and employees.
2024-12-12 Chinese
第五届监事会第六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the sixth meeting of the fifth Supervisory Board of Guangdong Yongshun Biopharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, and voting results. The content focuses on internal governance matters, specifically the approval of a stock incentive plan. There is no financial data, earnings information, or detailed report content. The document is not a full report but an official announcement of board/management decisions. Therefore, it fits best under Board/Management Information (MANG). The document length is short and it is not a report publication announcement or regulatory filing. Hence, the classification is MANG with high confidence.
2024-12-12 Chinese
关于2024年股权激励计划内幕信息知情人买卖公司股票情况的自查报告
Regulatory Filings Classification · 95% confidence The document is a self-inspection report regarding insider trading activities related to the company's 2024 equity incentive plan. It details the scope and procedures of the investigation, confirms no insider trading occurred, and references relevant regulatory compliance. The document is a regulatory compliance disclosure rather than a financial report, earnings release, or management announcement. It does not contain financial statements or detailed financial data. It fits best under Regulatory Filings (RNS) as it is a compliance-related announcement about insider trading checks and disclosures.
2024-12-12 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.